Drug Approval | April 24, 2023
USFDA suggests corrective measures to Sun Pharmaceutical’s Mohali facility
The USFDA had classified the inspection as "Official Action Indicated" (OAI).
The USFDA had classified the inspection as "Official Action Indicated" (OAI).
This is the first time the Agency has authorized the Phase 3 clinical evaluation in the U.S of a microbiota-based live biotherapeutic based on a pooling technology
The New State-of-Art OligoPilot 2000 solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs.
The interaction with key Government Officials and industry leaders led to a joint exploration of possible collaboration and investments in the Healthcare ecosystem between the two countries
Fully equipped labs with 75-member team set-up and made operational in <100 days
With a focus on optimizing patient experience with next-generation oral dosage forms, the US facility complements the cutting-edge research activities of Roquette’s existing pharma innovation centers in France and Singapore
Gafchromic films support patient care in oncology
Bayer reported the highest market capitalization growth of 23.1% during Q1 2023
Marksans will continue to supply existing products until the end of 2023 to Teva's affiliates, ensuring high-quality standards
This plant adds around 60,000 MT of capacity, scaling Jubilant Ingrevia Limited’s overall annual Acetic Anhydride capacity to 210,000 MT
Subscribe To Our Newsletter & Stay Updated
